Literature DB >> 11123106

The establishment and utility of a population-based registry to understand the epidemiology of systemic sclerosis.

M D Mayes1.   

Abstract

Epidemiologic studies establish a pattern of disease occurrence that predicts annual incidence (the number of new cases per year in a defined population), prevalence (the total number of cases in a defined population), and mortality. If this pattern changes over time or within certain groups, the assumption can be made that causal factors for disease expression are also changing. This information can lead to the development of testable hypotheses regarding disease causation and disease registries can provide a population for study. The autoimmune diseases are relatively rare, presenting a challenge to the epidemiologist. The Scleroderma Registry is a population-based census of systemic sclerosis in the Detroit, MI, area established to determine these baseline epidemiology parameters and to provide a framework to study this disease.

Entities:  

Mesh:

Year:  2000        PMID: 11123106     DOI: 10.1007/s11926-000-0029-3

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  22 in total

1.  Acute effect of nitric oxide on Raynaud's phenomenon in scleroderma.

Authors:  R R Freedman; R Girgis; M D Mayes
Journal:  Lancet       Date:  1999-08-28       Impact factor: 79.321

2.  Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma.

Authors:  R R Freedman; R Girgis; M D Mayes
Journal:  J Rheumatol       Date:  1999-11       Impact factor: 4.666

3.  Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial.

Authors:  J R Seibold; J H Korn; R Simms; P J Clements; L W Moreland; M D Mayes; D E Furst; N Rothfield; V Steen; M Weisman; D Collier; F M Wigley; P A Merkel; M E Csuka; V Hsu; S Rocco; M Erikson; J Hannigan; W S Harkonen; M E Sanders
Journal:  Ann Intern Med       Date:  2000-06-06       Impact factor: 25.391

Review 4.  Scleroderma epidemiology.

Authors:  M D Mayes
Journal:  Rheum Dis Clin North Am       Date:  1996-11       Impact factor: 2.670

5.  An epidemiological study of scleroderma in the West Midlands.

Authors:  A Silman; S Jannini; D Symmons; P Bacon
Journal:  Br J Rheumatol       Date:  1988-08

6.  Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963-1982.

Authors:  V D Steen; C V Oddis; C G Conte; J Janoski; G Z Casterline; T A Medsger
Journal:  Arthritis Rheum       Date:  1997-03

7.  Racial differences in scleroderma among women in Michigan.

Authors:  T J Laing; B W Gillespie; M B Toth; M D Mayes; R H Gallavan; C J Burns; J R Johanns; B C Cooper; B J Keroack; M C Wasko; J V Lacey; D Schottenfeld
Journal:  Arthritis Rheum       Date:  1997-04

8.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

9.  Connective tissue disease and autoantibodies in the kindreds of 63 patients with systemic sclerosis. The United Kingdom Systemic Sclerosis Study Group.

Authors:  P J Maddison; C Stephens; D Briggs; K I Welsh; G Harvey; J Whyte; N McHugh; C M Black
Journal:  Medicine (Baltimore)       Date:  1993-03       Impact factor: 1.889

10.  Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992.

Authors:  K M Uramoto; C J Michet; J Thumboo; J Sunku; W M O'Fallon; S E Gabriel
Journal:  Arthritis Rheum       Date:  1999-01
View more
  9 in total

1.  HLA-DRB1*0407 and *1304 are risk factors for scleroderma renal crisis.

Authors:  Binh Nguyen; Maureen D Mayes; Frank C Arnett; Deborah del Junco; John D Reveille; Emilio B Gonzalez; Hilda T Draeger; Marilyn Perry; Amir Hendiani; Kiran K Anand; Shervin Assassi
Journal:  Arthritis Rheum       Date:  2011-02

2.  Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis.

Authors:  Roozbeh Sharif; Marvin J Fritzler; Maureen D Mayes; Emilio B Gonzalez; Terry A McNearney; Hilda Draeger; Murray Baron; Daniel E Furst; Dinesh K Khanna; Deborah J del Junco; Jerry A Molitor; Elena Schiopu; Kristine Phillips; James R Seibold; Richard M Silver; Robert W Simms; Marilyn Perry; Carlos Rojo; Julio Charles; Xiaodong Zhou; Sandeep K Agarwal; John D Reveille; Shervin Assassi; Frank C Arnett
Journal:  J Rheumatol       Date:  2011-05-15       Impact factor: 4.666

3.  Antinuclear antibody-negative systemic sclerosis.

Authors:  Gloria A Salazar; Shervin Assassi; Fredrick Wigley; Laura Hummers; John Varga; Monique Hinchcliff; Dinesh Khanna; Elena Schiopu; Kristine Phillips; Daniel E Furst; Virginia Steen; Murray Baron; Marie Hudson; Suzanne S Taillefer; Janet Pope; Niall Jones; Peter Docherty; Nader A Khalidi; David Robinson; Robert W Simms; Richard M Silver; Tracy M Frech; Barri J Fessler; Jerry A Molitor; Marvin J Fritzler; Barbara M Segal; Firas Al-Kassab; Marilyn Perry; Jeremy Yang; Sara Zamanian; John D Reveille; Frank C Arnett; Claudia Pedroza; Maureen D Mayes
Journal:  Semin Arthritis Rheum       Date:  2014-11-28       Impact factor: 5.532

4.  Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines.

Authors:  Pravitt Gourh; Sandeep K Agarwal; Dipal Divecha; Shervin Assassi; Gene Paz; Rajpreet K Arora-Singh; John D Reveille; Sanjay Shete; Maureen D Mayes; Frank C Arnett; Filemon K Tan
Journal:  Arthritis Rheum       Date:  2009-12

5.  Risk of cancer in patients with scleroderma: a population based cohort study.

Authors:  C L Hill; A-M Nguyen; D Roder; P Roberts-Thomson
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

6.  Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls.

Authors:  Frank C Arnett; Pravitt Gourh; Sanjay Shete; Chul W Ahn; Robert E Honey; Sandeep K Agarwal; Filemon K Tan; Terry McNearney; Michael Fischbach; Marvin J Fritzler; Maureen D Mayes; John D Reveille
Journal:  Ann Rheum Dis       Date:  2009-07-12       Impact factor: 19.103

7.  Association of interleukin 23 receptor polymorphisms with anti-topoisomerase-I positivity and pulmonary hypertension in systemic sclerosis.

Authors:  Sandeep K Agarwal; Pravitt Gourh; Sanjay Shete; Gene Paz; Dipal Divecha; John D Reveille; Shervin Assassi; Filemon K Tan; Maureen D Mayes; Frank C Arnett
Journal:  J Rheumatol       Date:  2009-11-16       Impact factor: 4.666

8.  Major histocompatibility complex class I and class II alleles may confer susceptibility to or protection against morphea: findings from the Morphea in Adults and Children cohort.

Authors:  Heidi Jacobe; Chul Ahn; Frank C Arnett; John D Reveille
Journal:  Arthritis Rheumatol       Date:  2014-11       Impact factor: 10.995

9.  Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis.

Authors:  Pravitt Gourh; Frank C Arnett; Filemon K Tan; Shervin Assassi; Dipal Divecha; Gene Paz; Terry McNearney; Hilda Draeger; John D Reveille; Maureen D Mayes; Sandeep K Agarwal
Journal:  Ann Rheum Dis       Date:  2009-09-23       Impact factor: 19.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.